ALK and neoplasm: After many years of research, ALK-TKIs have been used to treat NSCLC patients with the ALK mutant gene, which could inhibit the growth of tumor cells by inhibiting tyrosine kinase and thereby destroying the signaling pathway (Lin et al., 2017).